<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102162</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202101979 -A</org_study_id>
    <secondary_id>OCR41108</secondary_id>
    <nct_id>NCT05102162</nct_id>
  </id_info>
  <brief_title>BL Infusion Trial: Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia</brief_title>
  <official_title>Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study plans to randomize a total of 240 patients infected with Gram-negative bacterial&#xD;
      pneumonia to receive beta-lactam (meropenem, cefepime, or piperacillin/tazobactam) continuous&#xD;
      or intermittent infusion and collect baseline and regular follow-up respiratory cultures to&#xD;
      assess the development of new resistance. The investigators will measure beta-lactam&#xD;
      concentration to assess the impact of drug exposure on the bacterial resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the incidence of Gram-negative bacterial resistance between patients treated with continuous and intermittent infusion beta-lactam regimens</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Continuous Antibiotic Dose Over 24 hours Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be receiving a continuous dose of antibiotic prescribed by their doctor for the duration they choose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent Antibiotic Dose Over 30 minutes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be receiving an intermittent dose of antibiotic prescribed by their doctor for the duration they choose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime, Meropenem, or Piperacillin/Tazobactam</intervention_name>
    <description>A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)</description>
    <arm_group_label>Continuous Antibiotic Dose Over 24 hours Arm</arm_group_label>
    <other_name>Maxipime, Merrem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefepime, Meropenem, or Piperacillin/Tazobactam</intervention_name>
    <description>A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)</description>
    <arm_group_label>Intermittent Antibiotic Dose Over 30 minutes</arm_group_label>
    <other_name>Maxipime, Merrem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admission to the medical ICU with severe pneumonia defined as per IDSA/ATS 2019&#xD;
             criteria on mechanical ventilation: presence of signs, symptoms and confirmatory chest&#xD;
             imaging consistent with pneumonia (e.g. fever, cough and pulmonary infiltrate by chest&#xD;
             radiograph) requiring mechanical ventilation due to respiratory failure&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  Positive rapid identification test and respiratory culture for Gram-negative bacteria&#xD;
             including, but not limited to, P. aeruginosa, K. pneumoniae, E. coli, S. marcescens,&#xD;
             H. influenzae, Enterobacter spp., M. catarrhalis, A. baumannii, Achromobacter spp., P.&#xD;
             mirabilis, and/or B. cepacia&#xD;
&#xD;
          -  Received within the last 48 hours or will receive meropenem, cefepime, or&#xD;
             piperacillin/tazobactam therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Allergy to the beta-lactams to be administered in this study&#xD;
&#xD;
          -  On renal replacement therapy at the time of randomization&#xD;
&#xD;
          -  Gram-negative bacteria identified by rapid testing only with negative respiratory&#xD;
             culture at baseline&#xD;
&#xD;
          -  COVID patients enrolled in other trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Alshaer, Pharm.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mohammad Alshaer, Pharm.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

